CAP TODAY Pathology/Laboratory Medicine/Laboratory Management
July 2017—The Binding Site’s Immunologicals Group has completed a major expansion to its monoclonal antibody product offerings. In addition to the company’s conjugated and unconjugated versions of the IgG4 Clone-HP6025 and the CD23 Clone BU-3438, a number of monoclonal antibodies focused on infectious diseases, including CMV, hepatitis (A, B, C, and D), herpes, HIV, rubella, and toxoplasma have been introduced. The antibodies exhibit outstanding degrees of specificity while demonstrating high levels of purity, extended shelf-life stability claims, and lot-to-lot consistencies, according to the company. The infectious diseases monoclonal antibodies are available in a standard size 1.0 mg fill format, while the rest come in a 0.2 mg fill format. Bulk packaging and customer-specific packaging options are also available.
The Binding Site, 800-633-4484